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ABSTRACT 
Objective 
To investigate the extent of and factors associated with incorrect dosing of antiretroviral 
therapy (ART) in HIV-infected children in Harare, Zimbabwe. 
Methods 
Children aged 0-17 years or under 35kgs (if aged >10 years), and taking ART were recruited 
from the paediatric HIV clinic at Harare Hospital. Their current doses of ART drugs were 
compared against doses recommended by the national guidelines.   
Results 
Among 309 children recruited (55% male, median age 7 years (IQR 5-10)), the median CD4 
count was 899 cells/mm3 and the median duration of their current ART regimen was 11.2 
months (IQR 4.9-17.1). Overall, 110 (35.6%) children were prescribed incorrect doses of at 
least one drug component within their ART regimen; 64 (20.7%) under-dosed and 49 
(15.9%) over-dosed on at least one drug. Children receiving a higher than recommended dose 
of ≥1 drug were younger (median 6 vs. 7 years, p=0.001), had a shorter time on their current 
ART regimen (median 7.2 vs. 13 months, p=0.003 and were less likely to be receiving a 
three-drug fixed-dose combination (FDC) (42.9% vs. 63.3%, p =0.009) compared to 
correctly-dosed children. Those who were under-dosed were also less likely to be on a three-
drug FDC (25% vs. 63.3%, p<0.001). 
Conclusions 
Over a third of children were prescribed incorrect doses of ART. Children taking triple-drug 
FDCs were likely to be correctly dosed. Our study highlights the importance of weight 
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monitoring at each clinical contact, training of healthcare providers on paediatric drug dosing 
and the need for wider availability of FDCs for children. 
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Background 
 
Of the estimated 1.8 million children under the age of 15 years living with HIV globally, 
nearly 90% are in sub-Saharan Africa (1). The scale-up of antiretroviral therapy (ART) has 
dramatically improved survival but challenges remain in achieving sustained virological 
suppression in children living with HIV in resource limited countries (3). With the paucity of 
pharmacodynamic (PD) and pharmacokinetic (PK) data in children, therapeutic ranges 
derived from adult ART data have been adapted for paediatric prescribing (4, 5).  
Drug PK and PD in children is affected by several factors including organ maturation and 
difference in drug metabolism and clearance, and changes in weight during growth (4-6). 
Body surface area-based dosing has been used in the past to define dosing ranges for 
children, but this method was often challenging to use in resource-limited settings and, 
therefore, weight-based dosing was introduced (7). Current international guidelines for 
paediatric ART recommend weight-based dosing with regular monitoring of a child’s weight 
and appropriate ART dose adjustment to avoid over- or under-dosing of ART drugs (12). 
We assessed paediatric ART prescribing in a large public-sector HIV clinic in Harare, 
Zimbabwe to understand if children are correctly dosed with ART, and factors associated 
with incorrect dosing.   
 
Methods 
Study site 
A cross-sectional study of children attending the paediatric HIV outpatient clinic at Harare 
Central Hospital, Zimbabwe, the largest public-sector hospital in Harare. An average of 100 
children (defined as individuals aged 0-17 year-olds) attend per day. ART is initiated by the 
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clinic doctor and children are reviewed by a doctor every three months (or more frequently if 
clinically indicated). At the doctor’s review the child’s height and weight is recorded and 
ART is prescribed for three months. If ART stocks do not allow for three monthly 
dispensation then children can be requested to return for a drug dispensing visit at either 1- or 
2- monthly intervals. On such a visit, children are reviewed by the clinic counsellor and/or 
nurse to assess ART adherence and ART is then dispensed (the child’s height and/or weight 
is not monitored at these dispensing visits). 
 
Study period and enrolment of participants 
Children aged 0-17 years, and those aged above 10 years but weighing less than 35 
kilogrammes (kgs) should receive weight-based dosing for ART according to Zimbabwe 
national guidelines (8). All children taking ART, who attended the clinic from the 1st May to 
31st July 2015, eligible for weight-based dosing and accompanied by a guardian were 
recruited. Only the first visit was included for children who attended on multiple occasions 
during the study period. The participant and guardian were interviewed, and clinical records 
were reviewed to collect data on demographics, CD4 cell count within the past six months, 
the current ART regimen, the date of initiation of current ART regimen and the most recent 
record of height, weight and ART dose (from the last doctor’s review). Verbal consent for a 
child to participate was obtained from the accompanying guardian and assent was obtained 
from the child. The study was approved by the Harare Central Hospital Ethics Committee. 
Antiretroviral therapy regimens 
ART prescribing followed national guidelines which recommended possible paediatric triple 
drug fixed dose combinations (FDCs), zidovudine/lamivudine/nevirapine (AZT/3TC/NVP). 
TDF containing combinations were only recommended in children over 10 years and >35kgs 
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and as an alternative second-line regimen. Other combinations were prescribed as a dual 
NRTI backbone (as an FDC) with a non-nucleotide reverse transcriptase inhibitor (NNRTI) 
or protease inhibitor (PI). 
 
Definitions of over-dosing and under-dosing of drugs  
Zimbabwean paediatric ART guidelines recommend weight-adjusted dose bands for 
individual ART drugs and FDCs. In this study, over-dosing was defined as drugs prescribed 
at a dose higher than recommended for the participant’s weight-band. A drug/FDC dosed 
below the weight-adjusted band was considered under-dosed. We considered children to be 
incorrectly dosed if they were either under- or over-dosed on at least one drug. Children 
could simultaneously be under-dosed for one drug component and over-dosed for another. 
 
Statistical analysis 
Data was entered in an electronic form on to Nexus 7 tablets. Statistical analysis was 
performed using Stata version 14 (Stata-Corp, TX, USA). The Mann-Whitney U-test was 
used to evaluate for differences between groups for continuous variables. For categorical 
variables, the χ2 test was used. The level of significance was set at α = 0.05.  
 
Results 
Study population 
During the study period, 2199 (71%) of 3111 children aged 0-17 years registered at the clinic 
were on ART. We enrolled 458 consecutive attendees over the study period; 309 were 
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eligible for weight-based dosing (age under 10 years or weight under 35kgs). The median age 
was 7 years (IQR 5-10); 55% (170) were male; 22 (7.1%) aged 0-2 years, 187 (60.5%) aged 
3-10 years and 100 (32.4%) aged 11-17 years and weighed <35kgs. The median CD4 cell 
count was 899 cells/mm3 (IQR 519-1287) and the median time on the current ART regimen 
was 11.2 months (IQR 4.9-17.1) Patient characteristics stratified by drug-dosage status are 
shown in Table 1. 
 
Antiretroviral therapy (ART) dosing 
The majority (98%, 304/309) of participants were prescribed ART that included an FDC: 163 
(52.8%) were on a triple drug FDC and 141 (45.6%) were on a dual drug FDC plus a third 
agent. Triple drug FDCs (152 on AZT/3TC/NVP and 11 on TDF/3TC/EFV) were prescribed 
in 1 (4.6%) child aged 0-2 years, 123 (65.8%) children aged 3-10 years and 39 (39.0%) 
children aged 11-17 years. A dual drug FDC (backbone) plus a third agent (87 on AZT/3TC, 
40 on TDF/3TC and 14 on ABC/3TC) were prescribed in 21 (95.5%) children aged 0-2 years, 
62 (33.2%) children aged 3-10 years and 58 (58%) children aged over 11-17 years. Overall, 
110 (35.6%) children were prescribed incorrect doses of at least one drug within their ART 
regimen; 49 (15.9%) children received higher doses of at least one drug and 64 (20.7%) were 
under-dosed on at least one drug.  
Drugs that were the most commonly over-dosed were 3TC in 49 (16%), AZT in 41 (17%) 
and NVP in 24 (13.8%) children receiving the respective drug. 3TC was under-dosed in 62 
(20.3%), AZT in 50 (20.8%) and EFV in 28 (50.9%) children (Figure 1). In children 
receiving a three-drug FDC, 21 (12.9%) were over-dosed for the NRTI and NNRTI 
components, while 27 (19.1%) children on dual-drug FDC were over-dosed for the NRTIs 
and the third drug component, which was in 16/71 children a PI and in 11/71 an NNRTI. 
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Factors associated with incorrect dosing 
The proportion of children incorrectly dosed on at least one drug varied by age; 7 (31.8%), 35 
(18.7%) and 7 (7.0%) of 0-2, 3-10 and 11-17-year olds respectively were over-dosed, 
p=0.004. Those on triple drug FDC, were more likely to have all three drugs correctly dosed 
compared to those on a dual drug FDC (plus a third agent) (77.3% vs, 51.1%, p<0.001).  
The proportion under-dosed was higher in younger compared to older children, with 8 
(36.4%) 0-2-year olds, 34 (18.2%) 3-10-year olds and 22 (22.0%) 11-17-year olds being 
under-dosed). Children who were under-dosed were less likely to be on a three-drug FDC 
(25% vs. 63.3%, p<0.001) compared to children receiving correct ART dosages. Children 
over-dosed on at least one drug component were younger (median 6 vs. 7 years, p=0.001, had 
a shorter time on their current ART regimen (median 7.2 vs. 13 months, p=0.003), and were 
also less likely to be receiving a three-drug FDC (42.9% vs. 63.3%, p =0.009) compared to 
children who were correctly dosed.  
 
Discussion 
This study demonstrates that over a third of children were incorrectly dosed on at least one of 
their ART drugs. Weight-based dosing is the mainstay of the Zimbabwean as well as other 
international paediatric ART guidelines with the use of FDCs simplifying ART regimens 
(8,12). Weight-based ART dosing can be challenging as a child’s weight changes with 
growth, and may drop during periods of acute illness, and doses may not be adjusted 
appropriately during these intervals. This was seen in the UK and Irish Collaborative HIV 
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Paediatric Study which demonstrated the proportion of children aged 2-12 years prescribed 
less than 90% of the recommended dose varied between 6% and 62% (9).  
Both over and under-dosing of drugs was observed in our study. Over-dosing may increase 
the risk of drug-related adverse events, e.g. EFV can be associated with significant 
neuropsychiatric adverse effects (10, 11). Recent guidelines have recommended a decrease in 
the EFV dose from 600mg to 400mg (12) based on findings showing that the lower dose led 
to fewer adverse events in adults (13). Under-dosing may increase risk of virological failure 
and promote development of drug resistance, both of which could impact on long-term 
treatment outcomes. This was seen in a cohort of HIV-infected children from Spain where 
treatment failure was significantly more frequent in children who were under-dosed than 
over-dosed (14). Routine viral load monitoring is often not accessible in resource limited 
countries, which increases the difficulties in identifying treatment failure early enough to 
prevent drug resistance. Precise ART dosing is therefore especially important in such 
settings.    
The majority of children were receiving FDC tablets with those on triple FDC being more 
likely to be correctly dosed than children receiving dual drug FDCs. Several studies have 
demonstrated that FDCs can be successfully used in children with sustained clinical and 
virological response (15, 16).  
We observed that frequency of weight monitoring was variable, and dosing was not reviewed 
at every ART dispensation. A child’s weight was only recorded at three-monthly doctor visits 
when ART is prescribed and at subsequent non-clinician visits (for ART collection) the 
children are not weighed and ART is not re-prescribed. The study was conducted in a 
secondary care facility-based HIV clinic, served by doctors. As HIV care is increasingly 
decentralised to lower level facilities, where there may be fewer and less well-trained staff, 
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and a lack of functioning equipment to monitor weight, incorrect paediatric ART dosing may 
be an even bigger issue. 
The study had several limitations: the study was cross-sectional and the type of visit 
(nurse/counsellor vs doctor visit) was not stipulated. However, it does highlight the 
importance of checking weight and reviewing drug doses at every visit. A review of the 
clinic’s policy on the frequency of a child’s visit and ARV prescribing is needed. 
Documentation of a child’s weight and review of ARV doses should be mandatory for every 
clinician review and ARV collection visits. Healthcare professionals who prescribe and 
dispense ARVs need to be adequately trained in monitoring a child’s weight and in 
recognising when ARV dose needs to be adjusted. Inadequate ARV supplies, heterogeneity 
of formulations and lack of paediatric formulations were concerns reported by the clinic staff. 
These factors may have contributed to the incorrect dosing. Further work is needed in 
reviewing ARV prescribing practice against national recommendations and the impact this 
has on ARV dosing and overall clinical outcome. A broader range of paediatric FDC 
formulations with a wider range of weight-band dosing is needed, which may alleviate 
suboptimal ARV dosing. 
Due to the lack of viral load monitoring and the cross-sectional design, we could not evaluate 
the relationship between incorrect drug dosing and virological outcomes, if there were any 
discontinuation associated with over-dosing, if the incorrect dosing had occurred since ART 
initiation or the duration in which the incorrect dosing had persisted. The sample size was 
relatively small and the sampling was consecutive with no age-stratified sampling. The study 
was conducted in a hospital-based HIV clinic, where HIV care is primarily delivered by 
doctors. With decentralisation of paediatric HIV care and treatment, nurse-led care is now 
standard of care and a similar study to investigate dosing in such settings is warranted.  
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In summary, this study has demonstrated a large proportion of children from a central urban 
clinic in Zimbabwe were prescribed suboptimal ART dosage and further research is required 
to investigate the extent of this problem and its impacts. Consistent availability of drugs, 
more user-friendly ART guidelines and adequate training and treatment monitoring facilities 
are essential to ensure children are prescribed correct ART doses. 
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Table 1. Characteristics of patients by drug-dosage status 
 
 
Total 
n=309 
Correct 
dosage for 
all ART 
drugs 
n=199 
Over-dosed 
on ≥1 drug 
n=49 
p-value 
correct vs. 
over-dosed 
Under-dosed 
on ≥1 drug 
n=64 
p-value 
correct vs. 
under-
dosed 
Male, n (%) 170 (55.0) 113 (56.8) 27 (55.1) 0.832 30 (46.9) 0.166 
Age at study visit 
(years), 
median (IQR) 
7 (5-10) 7 (5-11) 6 (3-8) 0.001 8 (5-10) 0.776 
Age at initiation of 
current regimen 
(years), 
median (IQR) 
6.5 (4-9.8) 6.8 (4.2-10.0) 5.2 (3.2-7.8) 0.003 7.4 (3.6-10.0) 0.672 
Time on current ART 
regimen (months),  
median (IQR) 
11.2  
(4.9-17.1) 
13 (5.3-17.6) 7.2 (3.5-12.1) 0.003 10.1 (5.4-19.3) 0.810 
Current weight (kg),  
median (IQR) 
21 (16-28) 22 (17-30) 17 (12-21) <0.001 23 (20-29) 0.959 
Current CD4 cell 
count (cells/µl), 
median (IQR)* 
899  
(519-1287) 
894  
(556-1260) 
959 (473-
1300) 0.933 912 (513-1445) 0.848 
Dual drug FDC,  
n (%) 
141 (45.6) 72 (36.2) 27 (55.1) 0.015 45 (70.3) <0.001 
Any three-drug FDC,  
n (%) 
163 (52.8) 126 (63.3) 21 (42.9) 0.009 16 (25) <0.001 
3TC lamivudine, ART antiretroviral therapy, AZT zidovudine, EFV efavirenz, FDC fixed-dose combination, NVP 
nevirapine, TDF tenofovir. 
*CD4 was considered current if measured within 6 months of the study visit. p-values are shown for the 
comparisons between correct dosing vs. over-dosing and correct dosing vs. under-dosing. One patient was 
missing the dose for the third drug component. 
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Figure 1: Daily drug doses according to weight for lamivudine, zidovudine, tenofovir, 
abacavir, nevirapine, efavirenz, lopinavir and atazanavir.  
 
 
 
The shaded rectangle represents the correct dosing for the respective weight band. The dots 
represent the actual weights of the children given the drug. The numbers above the dots 
represent the total number of children in the respective dosage category. The number of dots 
does not represent the number of children since dots corresponding to children with the same 
weight and drug dose would overlap. 
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